Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Iteos Therapeutics Inc ITOS

Healthcare Biotechnology
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448... see more

Recent & Breaking News (NDAQ:ITOS)

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire 3 days ago

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire November 12, 2024

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

GlobeNewswire October 24, 2024

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

GlobeNewswire September 14, 2024

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

GlobeNewswire August 20, 2024

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 8, 2024

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

GlobeNewswire August 5, 2024

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

GlobeNewswire July 8, 2024

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GlobeNewswire June 17, 2024

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 10, 2024

iTeos Therapeutics Announces $120 Million Registered Direct Offering

GlobeNewswire May 10, 2024

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire April 7, 2024

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

GlobeNewswire March 6, 2024

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire March 6, 2024

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire March 5, 2024

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire March 1, 2024

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

GlobeNewswire January 8, 2024

iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire November 21, 2023